Medicine
Zilbrysq 32.4 mg/0.81 mL injection
Zilbrysq 32.4 mg/0.81 mL injection is a prescription medicine containing Zilucoplan for subcutaneous use, marketed by UCB, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Storage as on the product label
Key facts
- Active ingredient (INN)
- Zilucoplan
- Brand
- Zilbrysq
- Strength
- 32.4 mg/0.81 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 4 cartons of 0.81 mL
- Marketing authorisation holder
- UCB
- Manufacturer
- UCB
- Origin register
- US FDA, United States
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AJ06 Zilucoplan
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 3 January 2024
- Identifiers
- NDC 50474-992Application NDA216834
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 4 carton in 1 box / 7 syringe, glass in 1 carton / .81 mL in 1 syringe, glass | 50474-992-80 | UCB | 3 January 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Zilucoplan
Clinical summary
Clinical information for Zilucoplan is on its overview page.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ZilucoplanFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- US FDA NDC directory · Checked 12 November 2026
- Zilbrysq: European public assessment report (EPAR) · European Medicines Agency
Need Zilbrysq 32.4 mg/0.81 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.